ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case-Control Study in Northern Sweden.
|
31805519 |
2020 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.
|
31485769 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.
|
30642093 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
CircWHSC1 promotes ovarian cancer progression by regulating MUC1 and hTERT through sponging miR-145 and miR-1182.
|
31666098 |
2019 |
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Olaparib is the first PARP inhibitor to be approved by the EMA and FDA for BRCA-mutated ovarian cancer.
|
27958297 |
2017 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
|
26973247 |
2016 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.
|
25998800 |
2015 |
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.
|
24551091 |
2014 |
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1.
|
24157791 |
2013 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer.
|
23933187 |
2013 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
MUC1 is aberrantly overexpressed by most ovarian cancer and regarded as a molecular target for ovarian cancer.
|
16925492 |
2006 |
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer.
|
15547734 |
2004 |
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study compares patterns of expression of MUC1 splice variants of malignant and benign ovarian tumours.
|
12115565 |
2002 |
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.
|
10389761 |
1999 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several ovarian CTL-TAL lines were developed that recognized in a non-MHC restricted fashion an Muc-1+ ovarian tumor, but not Muc-1-tumor.
|
7690810 |
1993 |